statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Head of Institutional Equities at HDFC Securities expects consumption demand to witness a slight pickup in FY25 and suggests adding exposure to the FMCG sector on a selective basis.

Daily Voice | These 4 pharma stocks to benefit from change in 2 trends: HDFC Securities' Unmesh Sharma

Net Sales are expected to decrease by 4.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs 6,290.9 crore, according to ICICI Securities.

Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities

Breach of 22,500-22,450 levels may trigger further profit booking, potentially towards 22,300 and beyond in the near term.

Hot Stocks: Here's why it's prudent to buy CDSL and sell Cipla for the short term

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

While most of the corporates have shown double digit value growth, unit growth remains a challenge for the Indian pharma market, according to analysts

Indian pharmaceutical market registers 9.5% growth in March

Cipla's Patalganga plant manufactures active pharmaceutical ingredients (APIs), the key raw materials for medicines, as well as formulations.

US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5%

Cipla will be responsible for the distribution of Sanofi India’s six central nervous system products, including Frisium, a leading brand in the anti-epileptic medication category

Cipla, Sanofi India shares gain on distribution agreement

Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated March 14, 2024.

Buy Cipla; target of Rs 1700: Sharekhan

Investigations revealed that Nectar Herbs and Drugs based in Uttarakhand was manufacturing and distributing counterfeit drugs. Brands such as GSK, Alkem, Aristo, and Cipla were among those exploited by the firm. Counterfeit versions of popular medications like Augmentin 625, Calvum-625, Omnicef-O 200, and Montclair LC were being produced at the illicit facility.

Maker of spurious antibiotics busted in Uttarakhand, big pharma companies exploited

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Volume	804,513.00
52-Wk High	1,519.00
52-Wk Low	896.85

CIPLA.NSE Cipla Ltd.

About

Feed

News

Sentiment

Fundamentals